Optimal sampling designs for estimation of Plasmodium falciparum clearance rates in patients treated with artemisinin derivatives

@inproceedings{Flegg2013OptimalSD,
  title={Optimal sampling designs for estimation of Plasmodium falciparum clearance rates in patients treated with artemisinin derivatives},
  author={Jennifer A. Flegg and Philippe J Guerin and François H Nosten and Elizabeth A Ashley and Aung Pyae Phyo and Arjen Mattheus Dondorp and Rick M. Fairhurst and Doung 7 Socheat and Steffen Borrmann and Anders B Bj{\"o}rkman and Andreas M{\aa}rtensson and Mayfong Mayxay and Paul Newton and Delia R. Bethell and Youry Se and Harald Noedl and Mahamadou Diakite and Abdoulaye A. Djimd{\'e} and Tran Tinh Hien and Nicholas J White and Kasia Stepniewska},
  booktitle={Malaria Journal},
  year={2013}
}
The emergence of Plasmodium falciparum resistance to artemisinins in Southeast Asia threatens the control of malaria worldwide. The pharmacodynamic hallmark of artemisinin derivatives is rapid parasite clearance (a short parasite half-life), therefore, the in vivo phenotype of slow clearance defines the reduced susceptibility to the drug. Measurement of parasite counts every six hours during the first three days after treatment have been recommended to measure the parasite clearance half-life… CONTINUE READING